Dutch biologicals firms are launching outside the EU first because approval takes too long
Invest-NL finds EU approval for a biological takes eight to ten years, pushing Dutch firms to launch in the UK, US and Brazil first.
AgNavigator reported on 5 November 2026 that Dutch companies in biological crop protection and precision fermentation are taking their first commercial products to markets outside the European Union, because approval inside it takes too long. The reporting draws on Deep Dive Agrifood Biotech, a study Invest-NL handed to the Dutch agriculture ministry on 30 October 2026. Its central figure is that European approval for a new biological crop protection product takes eight to ten years. Invest-NL calculates that faster commercialisation could add about 17 billion euros in annual Dutch revenue by 2040 across the three areas it studied.
VitalFluid, based in Eindhoven, controls fungal disease in crops without pesticides. Its first commercial deployment is with strawberry growers in the United Kingdom, which sits outside the European approval procedure, and its expansion is pointed at the United Kingdom and the United States. The company has raised 17 million euros, of which only about 2 million is being deployed in the Netherlands. “Dutch farmers want it too, but we don’t yet have approval from Brussels to bring it to market,” chief executive Erik Hertel told AgNavigator.
Vivici, which makes dairy proteins by precision fermentation, sells those proteins in the United States and manufactures at scale in India. Chief technology officer Marcel Wubbolts put the European novel food timetable at a legal minimum of 17 months, said he knows nobody who has reached the market inside three years in Europe, and put United States approval at about a year at most. Vivici raised 32.5 million euros in 2025, and roughly a quarter of that is going into manufacturing in India. “That money could have stayed in the Netherlands if there was a factory like that here,” Wubbolts said. A first commercial fermentation plant costs tens or hundreds of millions of euros.
The prize Invest-NL is measuring is large. It expects the global biological crop protection market to grow sevenfold to tenfold by 2040. For biotech ingredients and food applications it models about 8 billion euros a year of Dutch revenue by 2040 with the right measures, against about 2 billion euros under current policy, and it sees the Dutch share of that global market falling from roughly 3 per cent today to about 1 per cent without intervention. The study rests on more than 150 interviews with founders, investors, researchers and policymakers, plus investment data from 2010 to April 2026. Jellie Banga, chief business officer at Invest-NL, said the Netherlands is well positioned to lead in agri-food biotech but that the opportunity will not wait. Brazil appears in the report alongside the United States as a first launch market for biologicals.
What this means for AgTech founders: an approval clock of eight to ten years is not a regulatory footnote, it is the largest single input into your financing plan, and you should model it before you model anything else. Two patterns here are worth copying. Both companies kept their science in the Netherlands and moved the revenue abroad, which is the cheapest available answer to a slow home regulator, and European investors now expect to see that in a plan rather than discover it later. And the United Kingdom has become the nearest proving ground outside the EU for a European crop input, close enough that your own agronomists can attend the trials, and outside the queue in Brussels. The warning sits in the second half of the Vivici figure: a quarter of a 32.5 million euro round went to a factory in India, because that is where the plant could be financed. If your roadmap needs a first commercial facility, decide early whether you are building a European company with foreign production or a foreign company with European research, because the capital will make that choice for you if you do not. Then price the asymmetry honestly when you set your sequence. A product that can be sold in the United States or the United Kingdom within a year, while the European file matures over eight, gives you revenue to survive the wait. A plan that puts the EU first asks your investors to fund a decade of silence.
Dutch biologicals firms are launching outside the EU first because approval takes too long
Invest-NL puts European approval for a new biological crop protection product at eight to ten years. VitalFluid is selling into the United Kingdom, Vivici into the United States, and a quarter of a 32.5 million euro round went to a factory in India.
AgNavigator reported on 5 November 2026 that Dutch companies in biological crop protection and precision fermentation are taking their first commercial products to markets outside the European Union, because approval inside it takes too long. The reporting draws on Deep Dive Agrifood Biotech, a study Invest-NL handed to the Dutch agriculture ministry on 30 October 2026. Its central figure is that European approval for a new biological crop protection product takes eight to ten years. Invest-NL calculates that faster commercialisation could add about 17 billion euros in annual Dutch revenue by 2040 across the three areas it studied.
VitalFluid, based in Eindhoven, controls fungal disease in crops without pesticides. Its first commercial deployment is with strawberry growers in the United Kingdom, which sits outside the European approval procedure, and its expansion is pointed at the United Kingdom and the United States. The company has raised 17 million euros, of which only about 2 million is being deployed in the Netherlands. “Dutch farmers want it too, but we don’t yet have approval from Brussels to bring it to market,” chief executive Erik Hertel told AgNavigator.
Vivici, which makes dairy proteins by precision fermentation, sells those proteins in the United States and manufactures at scale in India. Chief technology officer Marcel Wubbolts put the European novel food timetable at a legal minimum of 17 months, said he knows nobody who has reached the market inside three years in Europe, and put United States approval at about a year at most. Vivici raised 32.5 million euros in 2025, and roughly a quarter of that is going into manufacturing in India. “That money could have stayed in the Netherlands if there was a factory like that here,” Wubbolts said. A first commercial fermentation plant costs tens or hundreds of millions of euros.
The prize Invest-NL is measuring is large. It expects the global biological crop protection market to grow sevenfold to tenfold by 2040. For biotech ingredients and food applications it models about 8 billion euros a year of Dutch revenue by 2040 with the right measures, against about 2 billion euros under current policy, and it sees the Dutch share of that global market falling from roughly 3 per cent today to about 1 per cent without intervention. The study rests on more than 150 interviews with founders, investors, researchers and policymakers, plus investment data from 2010 to April 2026. Jellie Banga, chief business officer at Invest-NL, said the Netherlands is well positioned to lead in agri-food biotech but that the opportunity will not wait. Brazil appears in the report alongside the United States as a first launch market for biologicals.
What this means for AgTech founders: an approval clock of eight to ten years is not a regulatory footnote, it is the largest single input into your financing plan, and you should model it before you model anything else. Two patterns here are worth copying. Both companies kept their science in the Netherlands and moved the revenue abroad, which is the cheapest available answer to a slow home regulator, and European investors now expect to see that in a plan rather than discover it later. And the United Kingdom has become the nearest proving ground outside the EU for a European crop input, close enough that your own agronomists can attend the trials, and outside the queue in Brussels. The warning sits in the second half of the Vivici figure: a quarter of a 32.5 million euro round went to a factory in India, because that is where the plant could be financed. If your roadmap needs a first commercial facility, decide early whether you are building a European company with foreign production or a foreign company with European research, because the capital will make that choice for you if you do not. Then price the asymmetry honestly when you set your sequence. A product that can be sold in the United States or the United Kingdom within a year, while the European file matures over eight, gives you revenue to survive the wait. A plan that puts the EU first asks your investors to fund a decade of silence.